Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21538542 | 0.75 | ACHE (0.35) | ACHECYP19A1 | |
| SCHEMBL18367683 | 0.74 | ACHE (0.33) | ACHE | |
| SCHEMBL24775851 | 0.72 | CYP19A1 (0.38) | CYP19A1 | |
| SCHEMBL21419598 | 0.68 | ACHE (0.36) | ACHECYP19A1 | |
| SCHEMBL18790863 | 0.68 | IDO1 (0.34) | CYP19A1 | |
| SCHEMBL21419563 | 0.67 | ACHE (0.35) | ACHE | |
| SCHEMBL22280519 | 0.67 | ACHE (0.35) | ACHE | |
| SCHEMBL24704471 | 0.65 | — | — | |
| SCHEMBL21953543 | 0.65 | CYP19A1 (0.38) | CYP19A1 | |
| SCHEMBL24253354 | 0.64 | CYP19A1 (0.37) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580820-B2 | Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof | KEMTECH S.R.L. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-8580820-B2 | Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof | KEMTECH S.R.L. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20110200581-A1 | PHARMACEUTICAL COMPOSITIONS | KEMOTECH S.r.I (IT) | 2011-08-18 | — | — | US | disclosed |
| US-20110200581-A1 | PHARMACEUTICAL COMPOSITIONS | KEMOTECH S.r.I (IT) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200581-A1 | PHARMACEUTICAL COMPOSITIONS | NR1H3, NR1H2, CCR8 | ACHE 3638/4885CYP19A1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.